<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849988</url>
  </required_header>
  <id_info>
    <org_study_id>ABP-19000</org_study_id>
    <nct_id>NCT04849988</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEON Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AEON Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 trial will evaluate the safety and efficacy of ABP-450 for the treatment of&#xD;
      cervical dystonia in adults. The study will enroll 60 patients across approximately 30 sites&#xD;
      in the United States. Study subjects will be divided evenly across a low dose group, a medium&#xD;
      dose group, a high dose group, and a placebo group for one treatment cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2 trial will evaluate the safety and efficacy of ABP-450 for the treatment of&#xD;
      cervical dystonia in adults. The study will enroll 60 patients across approximately 30 sites&#xD;
      in the United States. Study subjects will be divided evenly across a low dose, a medium dose&#xD;
      group, a high dose and placebo group for one treatment cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Approximately 60 patients will be randomized in a 1:1:1:1 ratio and receive one of the four treatments: ABP-450 low dose, ABP-450 mid dose, ABP-450 high dose, or placebo via intramuscular injection into affected neck muscles.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigator, study nurse/other study personnel, and patients will be blinded to the treatment group. An appropriately trained person will reconstitute investigational product, fill masked syringes and provide them to the blinded investigator, but will not perform any assessments with the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-related Serious Adverse Events</measure>
    <time_frame>Baseline up to 20 Weeks</time_frame>
    <description>The primary safety endpoint will be the incidence of treatment-related serious adverse events since the start of treatment by Treatment Group when dosed with placebo, ABP-450 (low dose), ABP-450 (mid dose), or ABP-450 (high dose).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score</measure>
    <time_frame>Baseline up to 20 weeks</time_frame>
    <description>The mean change in the total score of the TWSTRS since the start of treatment will be assessed by treatment group. The TWSTRS total score is a summation of the following subscales: Severity scale, Disability scale and Pain scale with a higher score representing a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the subscale score of severity of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)</measure>
    <time_frame>Baseline up to 20 weeks</time_frame>
    <description>The mean change in the subscale score of severity of the TWSTRS since the start of treatment will be assessed by Treatment Group. The higher score represents the greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the subscale score of disability of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Spasmodic Torticollis Rating Scale (TWSTRS)</measure>
    <time_frame>Baseline up to 20 weeks</time_frame>
    <description>The mean change in the subscale score of disability of the TWSTRS since the start of treatment will be assessed by Treatment Group. The higher score represents the greater disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the subscale score of pain of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)</measure>
    <time_frame>Baseline up to 20 weeks</time_frame>
    <description>The mean change in the subscale score of pain of the TWSTRS since the start of treatment will be assessed by Treatment Group. The higher score represents the greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Patient Global Impression of Change (PGI-C)</measure>
    <time_frame>Baseline up to 20 weeks</time_frame>
    <description>The mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale will be assessed by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Patient Global Impression of Severity (PGI-S)</measure>
    <time_frame>Baseline up to 20 weeks</time_frame>
    <description>The mean change in the subject's assessment of the severity of their condition since the start of treatment measured by the Patients' Global Impression of Severity (PGI-S) Scale will be assessed by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Clinical Global Impression of Change (CGI-C)</measure>
    <time_frame>Baseline up to 20 weeks</time_frame>
    <description>The mean change from Baseline in the Clinical Global Impression of Change (CGI-C) Score will be assessed by Treatment Group. CGI-C is a clinical assessment with a 7-point scale ranging from &quot;very much improved&quot; to &quot;very much worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Clinical Global Impression of Severity (CGI-S)</measure>
    <time_frame>Baseline up to 20 weeks</time_frame>
    <description>The mean change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score will be assessed by Treatment Group. CGI-S is a clinical assessment of the patient's illness severity on a 7-point scale ranging from &quot;normal&quot; to &quot;among the most extremely ill patients&quot;.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>ABP-450 - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABP-450 Low Dose - Intramuscular injections into affected neck muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABP-450 - Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABP-450 Mid Dose - Intramuscular injections into affected neck muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABP-450 - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABP-450 High Dose - Intramuscular injections into affected neck muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur.) - Intramuscular injections into affected neck muscles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP-450</intervention_name>
    <description>ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.</description>
    <arm_group_label>ABP-450 - High Dose</arm_group_label>
    <arm_group_label>ABP-450 - Low Dose</arm_group_label>
    <arm_group_label>ABP-450 - Medium Dose</arm_group_label>
    <other_name>prabotulinumtoxinA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients between 18 and 75 years of age (inclusive)&#xD;
&#xD;
          2. A clinical diagnosis of cervical dystonia (ie, spasmodic torticollis) defined by:&#xD;
&#xD;
               -  TWSTRS total score ≥20&#xD;
&#xD;
               -  TWSTRS severity score ≥10&#xD;
&#xD;
               -  TWSTRS disability score ≥3&#xD;
&#xD;
               -  TWSTRS pain score ≥1&#xD;
&#xD;
          3. On a stable dose of medications (if any) used for focal dystonia treatment (eg,&#xD;
             anticholinergics and benzodiazepines) for at least 3 months prior to and expected&#xD;
             throughout the study duration&#xD;
&#xD;
          4. For pre-treated patients only: Source documentation (eg, patient history) of the last&#xD;
             2 consecutive injection sessions with a botulinum toxin type A&#xD;
&#xD;
          5. For pre-treated patients only: At least 16 weeks must have passed between the last&#xD;
             injection with botulinum toxin for cervical dystonia and baseline treatment (patients&#xD;
             can be screened at Week 15 but cannot be enrolled until 16 weeks [for Day 0&#xD;
             injection])&#xD;
&#xD;
          6. Provided written informed consent to being treated for cervical dystonia with ABP-450&#xD;
&#xD;
          7. Stated willingness to comply with all study procedures, including attendance at the&#xD;
             study center for all study visits as scheduled and have technological capabilities to&#xD;
             have televisits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Traumatic torticollis or tardive torticollis&#xD;
&#xD;
          2. Predominant retrocollis or anterocollis&#xD;
&#xD;
          3. Myotomy or denervation surgery in the affected muscles (eg, peripheral denervation&#xD;
             and/or spinal cord stimulation)&#xD;
&#xD;
          4. Hypersensitivity to human serum albumin, sucrose, or botulinum toxin type A&#xD;
&#xD;
          5. Previous treatment for cervical dystonia with rimabotulinumtoxin B&#xD;
&#xD;
          6. Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis,&#xD;
             or any other significant neuromuscular disease that might interfere with the trial&#xD;
&#xD;
          7. Current swallowing disorder of any origin (dysphagia scale ≥3, ie, severe, with&#xD;
             swallowing difficulties and requiring a change in diet)&#xD;
&#xD;
          8. Marked limitation on passive range of motion that suggests contractures or other&#xD;
             structural abnormality, eg, cervical contractures or cervical spine syndrome&#xD;
&#xD;
          9. Treatment with botulinum toxins of any type for any indication other than cervical&#xD;
             dystonia within 16 weeks prior to baseline and during the study&#xD;
&#xD;
         10. Medical or psychiatric conditions that may increase the risk associated with study&#xD;
             participation or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for entry into this&#xD;
             study&#xD;
&#xD;
         11. Participation in another interventional study during participation in this study&#xD;
&#xD;
         12. Pregnant or lactating females, or females of child-bearing potential not willing to&#xD;
             use an acceptable method of contraception (ie, intrauterine device, barrier methods&#xD;
             with spermicide, or abstinence)&#xD;
&#xD;
         13. For pre-treated patients only: The patient's most recent injection with botulinum&#xD;
             toxin exceeding the number of units specified as follows:&#xD;
&#xD;
               -  OnabotulinumtoxinA (BOTOX®): &gt;300 units&#xD;
&#xD;
               -  IncobotulinumtoxinA (Xeomin®): &gt;300 units&#xD;
&#xD;
               -  AbobotulinumtoxinA (Dysport®): &gt;750 units&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Comella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Jankovic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor St. Luke's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Del Stagg, PhD</last_name>
    <phone>949-354-6424</phone>
    <email>ds@aeonbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Neuroscience Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciria Luevano</last_name>
      <phone>602-482-2116</phone>
      <email>research@centerforneurologyandspine.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Gitt, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Movement Disorders Center of Arizona, LLC</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danica Evidente</last_name>
      <phone>480-526-5441</phone>
      <email>info@movementdisorders.us</email>
    </contact>
    <investigator>
      <last_name>Virgilio G Evidente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's and Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Malhas</last_name>
      <phone>714-378-5074</phone>
    </contact>
    <investigator>
      <last_name>Daniel Truong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhu Chowdhary</last_name>
      <phone>559-437-8700</phone>
      <phone_ext>312</phone_ext>
    </contact>
    <investigator>
      <last_name>Perminder Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Nembhard</last_name>
      <phone>954-366-0277</phone>
    </contact>
    <investigator>
      <last_name>Harvey Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Neurology Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leanne Rodriguez</last_name>
      <phone>305-596-2080</phone>
    </contact>
    <investigator>
      <last_name>Brad Herskowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology One</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Duvall</last_name>
      <phone>407-916-0304</phone>
      <email>info@neurologyone.net</email>
    </contact>
    <investigator>
      <last_name>Ramon Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroStudies.net</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Hillard</last_name>
      <phone>404-475-0552</phone>
    </contact>
    <investigator>
      <last_name>Marshall Nash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute - Hunt - PPDS</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>248-957-8940</phone>
    </contact>
    <investigator>
      <last_name>Aaron Ellenbogen, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Orthopedic Foundation</name>
      <address>
        <city>New Albany</city>
        <state>Ohio</state>
        <zip>43054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Showe</last_name>
      <phone>614-533-5556</phone>
    </contact>
    <investigator>
      <last_name>Martin Taylor, DO, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veracity Neuroscience LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Nelson</last_name>
      <phone>901-237-3561</phone>
    </contact>
    <investigator>
      <last_name>Mark LeDoux, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Jones</last_name>
      <phone>615-936-0060</phone>
    </contact>
    <investigator>
      <last_name>David Charles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology Consultants PA</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koni Lopez</last_name>
      <phone>512-218-1222</phone>
      <phone_ext>214</phone_ext>
    </contact>
    <investigator>
      <last_name>Elizabeth Peckham, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data collected during the trial, after deidentification may be shared following review of the clinical study report by the FDA review division and if a decision is made to publish the results in a publication outside posting the results in clinicaltrials.gov.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

